期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 66, 期 1, 页码 122-139出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01599
关键词
-
Research on the three isoforms of protein kinase D (PKD1, PKD2, and PKD3) has matured over the past three decades. Medicinal chemistry has provided a diverse set of active site inhibitors, but they have not been tested in clinical trials yet. There is a need for potent and selective PKD modulators to address unresolved medical needs in various diseases.
Now entering its fourth decade, research on the biological function, small molecule inhibition, and disease relevance of the three known isoforms of protein kinase D, PKD1, PKD2, and PKD3, has entered a mature development stage. This mini-perspective focuses on the medicinal chemistry that provided a structurally diverse set of mainly active site inhibitors, which, for a brief time period, moved through preclinical development stages but have yet to be tested in clinical trials. In particular, between 2006 and 2012, a rapid expansion of synthetic efforts led to several moderately to highly PKD-selective chemotypes but did not yet achieve PKD subtype selectivity or resolve general toxicity and pharmacokinetic challenges. In addition to cancer, other unresolved medical needs in cardiovascular, inflammatory, and metabolic diseases would, however, benefit from a renewed focus on potent and selective PKD modulators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据